Neuropace Inc. (NPCE) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Neuropace Inc. (NPCE) advanced +0.62% to $13.01, trading at 37% of its 52-week range ($9.22 – $19.6). Stretched risk/reward at current multiples (-23% return on capital) under elevated 10-year interest-rate pressure.
MOUNTAIN VIEW, Calif., October 29, 2026--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +25.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NPCE today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NPCE. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Neuropace Inc. (NPCE) ranks #941 by composite RQD confidence (30/100, grade E) and #467 by equity capitalization ($446.6M). Within this direct 5-issuer industry benchmark cohort, NPCE leads on earnings valuation at N/A trailing P/E, while OFIX leads on capital efficiency and profitability with -12.2% ROIC and 68.8% gross margin. OFIX currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with NPCE at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NPCE
ACTIVE
Neuropace Inc. | E | 30/100 | — | 77.2% | -23.0% | +0.62% | $446.6M | Benchmark Subject |
| CARL Carlsmed Inc. | D- | 39/100 | — | 75.3% | -35.0% | +3.01% | $430.6M | /carl-vs-npce → |
| SI Shoulder Innovations Inc. | D- | 42/100 | — | 76.5% | -16.1% | +4.93% | $425.5M | /si-vs-npce → |
| SSII SS Innovations International Inc. | D- | 39/100 | — | 46.0% | -18.5% | -2.46% | $477.2M | /ssii-vs-npce → |
| OFIX Orthofix Medical Inc. | D+ | 55/100 | — | 68.8% | -12.2% | +1.99% | $417.1M | /ofix-vs-npce → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neuropace Inc. (NPCE) reported GAAP revenue of $100.0M (+25.1% vs. FY2024 revenue of $79.9M , and +52.8% cumulative change since FY2023) , GAAP net income of -$21.5M, operating cash flow of -$11.0M, and free cash flow of -$11.3M (+37.9% YoY). On the balance sheet, NPCE closed FY2025 with $105.6M in total assets against $58.9M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $100.0M | -$21.5M | -$11.0M | -$11.3M | $105.6M | $58.9M |
| FY2024 (FY) | 2024-12-31 | $79.9M | -$27.1M | -$17.9M | -$18.3M | $94.6M | $59.5M |
| FY2023 (FY) | 2023-12-31 | $65.4M | -$33.0M | -$19.7M | -$19.7M | — | — |
As of 2026-11-01, Neuropace Inc. (NASDAQ: NPCE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $13.01 (+0.62% 1D, market cap $446.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NPCE ranks #941 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), NPCE carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 77.2%, and ROIC of -23.0%. By comparison, CARL (Carlsmed Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $430.6M) and SI (Shoulder Innovations Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -16.1%, cap $425.5M). Among the 5-stock peer group, NPCE leads on earnings multiple (N/A) while OFIX leads on capital efficiency (-12.2% ROIC).
Per NPCE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001528287), Neuropace Inc. generated $100.0M in revenue (+25.1% YoY), -$21.5M in net income, and -$11.3M in free cash flow against $105.6M in total assets and $58.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
NPCE last traded at $13.01 (+0.62% on volume of 104,579 shares), positioning the stock -4.90% below its 50-day simple moving average ($13.68) and -13.15% below its 200-day simple moving average ($14.98). Across its 52-week range of $9.22 to $19.60, NPCE sits at the 36.5% percentile with a 14-day RSI of 39.3 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($11.76 to $14.26).
Why NPCE Stock advanced +0.62% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-23% return on capital) under elevated 10-year interest-rate pressure.